000303038 001__ 303038
000303038 005__ 20250723114148.0
000303038 0247_ $$2doi$$a10.1016/j.redox.2025.103755
000303038 0247_ $$2pmid$$apmid:40690813
000303038 037__ $$aDKFZ-2025-01485
000303038 041__ $$aEnglish
000303038 082__ $$a570
000303038 1001_ $$0P:(DE-He78)a9f5a6e80270aef6347a340d52c893c1$$aCui, Zhixin$$b0$$eFirst author$$udkfz
000303038 245__ $$aAssociations of selenium status with all-cause and cause-specific mortality: a systematic review and meta-analysis of cohort studies.
000303038 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2025
000303038 3367_ $$2DRIVER$$aarticle
000303038 3367_ $$2DataCite$$aOutput Types/Journal article
000303038 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1753189571_32230
000303038 3367_ $$2BibTeX$$aARTICLE
000303038 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303038 3367_ $$00$$2EndNote$$aJournal Article
000303038 500__ $$a#EA:C070#LA:C070#
000303038 520__ $$aTo provide a systematic review and meta-analysis of population-based cohort studies on the association of selenium status with all-cause and cause-specific mortality.Relevant studies were identified through systematic searches of MEDLINE and ISI Web of Knowledge. Risk ratios (RRs) reported across categories of selenium biomarkers were recalculated as continuous RR estimations per standard deviation (SD) using generalized least squares for linear trend estimation and pooled in random effects meta-analyses.The literature search identified 20 studies, including 17 studies on all-cause mortality, 9 studies on cardiovascular mortality and 7 on cancer mortality. An increase of selenium biomarker concentration by one SD was associated with 13 % lower all-cause mortality (RR [95 %-confidence interval], 0.87 [0.83-0.90]), 11 % lower cardiovascular mortality (0.89 [0.84-0.94]) and 15 % lower cancer mortality (0.85 [0.78-0.94]). Although moderate heterogeneity was observed, the inverse association with all-cause mortality was robust across countries with low or adequate selenium supply, selenium measurement methods, recruitment years, study quality scores, follow-up lengths and sample sizes. The trim and fill method showed no indications of relevant publication bias.Selenium biomarkers are inversely associated with all-cause, cardiovascular and cancer mortality in the general population and clinical trials among selenium deficient populations are still needed.
000303038 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000303038 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303038 650_7 $$2Other$$aCancer
000303038 650_7 $$2Other$$aCardiovascular diseases
000303038 650_7 $$2Other$$aCohort studies
000303038 650_7 $$2Other$$aMeta-analysis
000303038 650_7 $$2Other$$aMortality
000303038 650_7 $$2Other$$aSelenium
000303038 650_7 $$2Other$$aSystematic review
000303038 7001_ $$0P:(DE-He78)7089188e1b7bdb788ba48ba96f21df07$$aXie, Ruijie$$b1$$udkfz
000303038 7001_ $$aLu, Xiaoting$$b2
000303038 7001_ $$aSchomburg, Lutz$$b3
000303038 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$udkfz
000303038 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b5$$eLast author$$udkfz
000303038 773__ $$0PERI:(DE-600)2701011-9$$a10.1016/j.redox.2025.103755$$gVol. 85, p. 103755 -$$p103755$$tRedox Biology$$v85$$x2213-2317$$y2025
000303038 909CO $$ooai:inrepo02.dkfz.de:303038$$pVDB
000303038 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9f5a6e80270aef6347a340d52c893c1$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000303038 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7089188e1b7bdb788ba48ba96f21df07$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000303038 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000303038 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000303038 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000303038 9141_ $$y2025
000303038 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bREDOX BIOL : 2022$$d2024-12-16
000303038 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000303038 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000303038 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-06-05T07:04:07Z
000303038 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-06-05T07:04:07Z
000303038 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-06-05T07:04:07Z
000303038 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000303038 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-16
000303038 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000303038 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-16
000303038 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000303038 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000303038 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bREDOX BIOL : 2022$$d2024-12-16
000303038 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-16
000303038 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-16
000303038 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000303038 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000303038 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie der Krebsfrüherkennung$$x0
000303038 980__ $$ajournal
000303038 980__ $$aVDB
000303038 980__ $$aI:(DE-He78)C070-20160331
000303038 980__ $$aUNRESTRICTED